Stockscreener 앱 받기
3.58
0.56%
-0.02
시간 외 거래:
3.69
0.11
+3.07%
전일 마감가:
$3.60
열려 있는:
$3.64
하루 거래량:
746.12K
Relative Volume:
0.54
시가총액:
$290.57M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+9.48%
1개월 성능:
+36.64%
6개월 성능:
+13.65%
1년 성능:
+0.00%
1일 변동 폭
$3.445
$3.65
1주일 범위
$3.19
$3.67
52주 변동 폭
$1.42
$4.66
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
3.58 | 290.57M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
aTyr Pharma, Inc.'s (NASDAQ:ATYR) Path To Profitability - simplywall.st
Wells Fargo & Company MN Invests $383,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Atyr Pharma Inc [ATYR] Records 200-Day SMA of $2.90 - knoxdaily.com
There is no doubt that Atyr Pharma Inc (ATYR) ticks all the boxes. - Sete News
How should investors view Atyr Pharma Inc (ATYR)? - uspostnews.com
JPMorgan Chase & Co. Boosts Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewswire
aTyr Pharma Presents Preclinical Data for NRP2-Targeting - GlobeNewswire
When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit? - Yahoo Finance
Leerink Partners gives an Outperform recommendation for Atyr Pharma Inc (ATYR) - knoxdaily.com
aTyr Pharma presents preclinical data on ATYR2810 at AACR - TipRanks
aTyr Pharma (ATYR) Reveals Promising Preclinical Data on Cancer Treatment | ATYR Stock News - GuruFocus
Market Watch Highlights: Atyr Pharma Inc (ATYR) Ends on an Downturn Note at 3.27 - DWinneX
Atyr Pharma Inc (NASDAQ: ATYR) Stock: More Upside Ahead? - Marketing Sentinel
Breakthrough: Novel Antibody ATYR2810 Extends Survival in Aggressive Brain Cancer Trial - Stock Titan
Geode Capital Management LLC Buys Shares of 891,407 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Director Gross Jane A acquire 3,750 shares of Atyr Pharma Inc [ATYR] - knoxdaily.com
Analytical Lens: Exploring Atyr Pharma Inc (ATYR)’s Financial Story Through Ratios - DWinneX
Atyr PHARMA (ATYR) to Release Quarterly Earnings on Thursday - Defense World
Watch this stock’s price performance: Atyr Pharma Inc (NASDAQ:ATYR) - uspostnews.com
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock By Investing.com - Investing.com Canada
Solid Biosciences (NASDAQ:SLDB) versus Atyr PHARMA (NASDAQ:ATYR) Head to Head Comparison - Defense World
Atyr Pharma Inc (ATYR) receives an Outperform rating from Leerink Partners - knoxdaily.com
Cantor maintains Overweight on aTyr Pharma stock ahead of trials By Investing.com - Investing.com Canada
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
Raymond James Financial Inc. Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
American Century Companies Inc. Makes New $319,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
American Century Companies Inc. Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR) - The AM Reporter
Atyr PHARMA INC (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World
US High Growth Tech Stocks to Watch in 2023 - simplywall.st
aTyr Pharma to Participate in April Investor Conferences - GlobeNewswire
Biotech Innovator aTyr Pharma Sets Key Investor Meetings at Premier Healthcare Conferences - Stock Titan
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments - Markets Insider
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Atyr Pharma Inc 주식 (ATYR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
| SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
| SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
| SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
| DENYES NANCY | General Counsel |
Jun 05 '24 |
Buy |
1.86 |
5,000 |
9,276 |
22,267 |
| COUGHLIN TIMOTHY | Director |
May 30 '24 |
Buy |
1.75 |
50,000 |
87,500 |
56,000 |
| Broadfoot Jill Marie | Chief Financial Officer |
May 31 '24 |
Buy |
1.79 |
5,000 |
8,950 |
27,960 |
| Shukla Sanjay | President and CEO |
May 31 '24 |
Buy |
1.81 |
20,000 |
36,140 |
136,548 |
0.39%
3.66%
자본화:
|
볼륨(24시간):